Jupiter Neurosciences Licenses ALA-002 from PharmAla Biotech in $100M Deal
Jupiter Neurosciences (Nasdaq: JUNS) has signed a licensing agreement with PharmAla Biotech for exclusive U.S. rights to ALA-002, a patented formulation of MDMA, valued at up to $100 million including milestones. This deal positions Jupiter as a dual clinical-stage CNS company and expands its portfolio alongside an ongoing Phase II trial in Parkinson's disease.
Topics: Clinical Trials Licensing Agreement Neuroscience Psychedelics